$4.20
0.020.48%
Last update: Nov 10, 8:36 AM
Opus Genetics Inc
IRDNASDAQ
Opus Genetics rose 113.2% from $1.97 to $4.20, ahead of the S&P 500's +10.5%. Its worst day was Jun 5 (−13.1%), and its low came Nov 17 at $1.74.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.25 missed the $-0.13 estimate on $3.1M revenue (est. $3.0M).
−2.5% · S&P 500 +0.1%
Opus Genetics shares rose 16.7%, while the S&P 500 rose 1.9%.
Story events cover the past 12 months · Times ET
+16.7% · S&P 500 +1.9%
Opus Genetics shares rose 15.9%, while the S&P 500 fell 0.5%.
+15.9% · S&P 500 −0.5%
EPS of $-0.21 missed the $-0.10 estimate on $3.9M revenue (est. $2.9M).
+1.7% · S&P 500 −0.2%
EPS of $-0.75 missed the $-0.14 estimate on $2.2M revenue (est. $2.9M).
+1.2% · S&P 500 −0.2%
Opus Genetics shares fell 13.1%, while the S&P 500 fell 2.6%.
−13.1%, the year's worst day · S&P 500 −2.6%
EPS of $-0.14 beat the $-0.16 estimate on $755,000.00 revenue (est. $2.7M).
−1.6% · S&P 500 −0.2%
Topline data from Phase 1/2 Cohort 1 of OPGx-BEST1 gene therapy program to be presented during investor conference call and webcast on September 9 at 8:00 a.m.
+16.2% · S&P 500 +0.4%
Opus Genetics closed at its highest level of the year, 208.1% above where the year started.
+5.9% · S&P 500 −0.6%
Where it ended: a close of $4.20 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 10, 2026 (EPS est. $-0.15, revenue est. $2.1M).
Nothing in the past 12 months.
All IRD dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for IRD and SPY from Benzinga historical bars. Not investment advice.
